PRESS RELEASE. Sciety and the network Sciety Venture Partners have invested SEK 68 million in the Swedish radioimmunotherapy company Akiram Therapeutics. The investment company Linc AB participated in the share issue with SEK 20 million. Akiram is developing a new type of targeted radiotherapy against incurable cancer that has shown
PRESS RELEASE. The Sciety syndicate has invested SEK 26 million in Swedish health tech company Encare, whose SaaS solution enables health care providers to improve surgery outcomes. The new capital will finance Encare’s global expansion and further develop the company’s products. Around 300 million surgeries are performed worldwide annually, and
PRESS RELEASE. The Swedish pharmaceutical company PharmNovo, which is developing a new type of drug for nerve pain, has raised SEK 67 million in a new share issue led by Sciety. Karolinska Development AB participated in the share issue with SEK 20 million. The new capital will be used to
PRESS RELEASE. Capitainer, a Swedish MedTech company supplying reliable solutions for self-sampling of blood and plasma, has raised a further SEK 34 million with Sciety and its investment syndicate in a new share issue. The company will use the proceeds to fund additional product validations, sales, and marketing to meet
NEW COMPANY AT SCIETY. Long waiting time for surgery, deficiencies in patient safety, and high costs for care related to surgery. Healthcare faces significant challenges in Sweden and internationally while the demands for quality-improving measures are increasing. A Swedish health-tech player with an IT solution implementing structure and systematics in
PRESS RELEASE. Sciety recently made an investment of over SEK 58 million in the cell therapy company NEOGAP Therapeutics, which is developing personalised immunotherapy for the treatment of cancer. The new capital will be used for a clinical phase I/II trial in colorectal cancer with an estimated start in 2022.
Sciety is a capital partner specialising in life science and healthcare, offering services in capital raising and related areas. Sciety may currently have, may previously have had or may in the future be engaged by companies mentioned in our communications or operating in the sectors described, and may hold ownership interests in such companies. Sciety receives remuneration for its services, including commissions in connection to capital raises. Our communication is intended for informational purposes only and does not constitute personal investment advice. We do not guarantee the accuracy, completeness or timeliness of the information provided. Investment decisions should not be based solely on this communication.